Orphan status for GW’s rare epilepsy drug
admin 30th March 2017 Uncategorised 0London, UK-based GW Pharmaceuticals’ cannabinoid Epidiolex has been awarded Orphan status by European regulators as a treatment for Lennox-Gastaut Syndrome (LGS), a rare and severe form of childhood-onset epilepsy.
More: Orphan status for GW’s rare epilepsy drug
Source: News